Based on available evidence, biomarkers are strongly featured in recommendations for management of patients on anthracyclines, anti-HER2 antagonists, immunotherapy, proteasome inhibitors, and VEGF inhibitors as well as patients being evaluated for amyloidosis. This evidence concerns the gene ERBB2 and amyloidosis.